Industry
Biotechnology
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 22, 2024 | 11:51 am
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 4:48 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 12:03 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 11:14 am
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 12:04 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 12:03 pm
Portfolio Pulse from Benzinga Newsdesk
July 01, 2024 | 10:55 am
Portfolio Pulse from Avi Kapoor
June 18, 2024 | 12:39 pm
Portfolio Pulse from Benzinga Newsdesk
June 18, 2024 | 9:01 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.